A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.

Trial Details

NCT ID
NCT07405151
Phase
PHASE1 / PHASE2
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • I-DXd
  • Rescue Medication
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Natal, Rio Grande do Norte, Brazil|-5.795,-35.20944
  • Porto Alegre, Rio Grande do Sul, Brazil|-30.03283,-51.23019
  • Santiago, Region M. de Santiago, Chile|-33.45694,-70.64827
  • Santiago, Region M. de Santiago, Chile|-33.45694,-70.64827

Key Eligibility Criteria

  • Has a histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
  • Has disease progression after 1 or 2 prior lines of systemic therapy for unresectable locally advanced or metastatic ESCC
  • Has measurable disease
  • If infected with human immunodeficiency virus (HIV), has well-controlled HIV on antiretroviral therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →